Table 1 Patient clinicopathological characteristics in probiotics and placebo groups
From: A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer
Parameters | Probiotic (n = 27) | Placebo (n = 25) | |
|---|---|---|---|
Age in years (mean ± SD) | 67.33 ± 9.44 | 66.5 ± 8.57 | |
Gender (n, %) | Male | 19 (70.4) | 15 (60.0) |
Female | 8 (29.6) | 10 (40.4) | |
Smoking status (n, %) | Smoker | 8 (29.6) | 4 (16.0) |
Ex- smoker | 4 (24.8) | 10 (56.0) | |
Non smoker | 15 (55.6) | 11 (44.0) | |
Comorbidities (n, %) | Hypertension | 2 (7.4) | 2 (8.0) |
Hypertension & Dyslipidaemia | 9 (33.3) | 9 (36.0) | |
Diabetes Mellitus(DM), Hypertension & Dyslipidaemia | 2 (7.4) | 2 (11.1) | |
Chronic Kidney Disease, Hypertension, DM | 2 (7.4) | – | |
Chronic Heart Disease, Hypertension, Dyslipidaemia | – | 1 (4.0) | |
Stage (n %) | I | 1 (.37) | 1 (4.0) |
II | 8 (29.6) | 5 (20.0) | |
III | 18 (66.7) | 19 (76.0) | |
IV | – | – | |
Differentiation | Well differentiated | 9 (33.3) | 5 (20.0) |
Moderately differentiated | 18 (66.7) | 20 (80.0) | |
Poorly differentiated | |||
Location | Right | 1 (3.7) | 1 (4.0) |
Left | 26 (96.3) | 24 (96.0) | |
Infection during product consumption (n, %) | – | – | |
Received adjuvant therapy (n, %) | 8 (29.6) | 6 (24.0) | |
Chemotherapy induced diarrhoea (n, %) [CTCAE V 3.0] | 6 (22.2) | 5 (20.0) | |